Abstract
Background: The polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age and shows substantial phenotypic variability. According to the presence of the three diagnostic criteria of PCOS, i.e. oligo- and/or anovulation, hyperandrogenemia and/or clinical signs of high androgen levels, and polycystic ovaries, four different phenotypes of PCOS are identified. It appears that these phenotypes differ in the prevalence of several established and emerging cardiovascular risk factors. Methods: We searched the literature for studies that compared the cardiovascular risk profile of patients with the different phenotypes of PCOS. Results: Patients with both anovulation and hyperandrogenemia have more pronounced insulin resistance and higher levels of proinflammatory and prothrombotic mediators than patients with polycystic ovaries and either anovulation or hyperandrogenemia. Conclusion: Given that these differences appear to be mainly driven by the more pronounced obesity of the former patients, diet and exercise aiming at weight loss should constitute the cornerstone of management of PCOS and should be particularly emphasized in patients with the higher risk phenotypes of the syndrome.
Keywords: Polycystic ovary syndrome, phenotypes, diagnostic criteria, anovulation, hyperandrogenemia, polycystic ovaries, cardiovascular risk.
Current Pharmaceutical Design
Title:Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome
Volume: 22 Issue: 36
Author(s): Konstantinos Tziomalos
Affiliation:
Keywords: Polycystic ovary syndrome, phenotypes, diagnostic criteria, anovulation, hyperandrogenemia, polycystic ovaries, cardiovascular risk.
Abstract: Background: The polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age and shows substantial phenotypic variability. According to the presence of the three diagnostic criteria of PCOS, i.e. oligo- and/or anovulation, hyperandrogenemia and/or clinical signs of high androgen levels, and polycystic ovaries, four different phenotypes of PCOS are identified. It appears that these phenotypes differ in the prevalence of several established and emerging cardiovascular risk factors. Methods: We searched the literature for studies that compared the cardiovascular risk profile of patients with the different phenotypes of PCOS. Results: Patients with both anovulation and hyperandrogenemia have more pronounced insulin resistance and higher levels of proinflammatory and prothrombotic mediators than patients with polycystic ovaries and either anovulation or hyperandrogenemia. Conclusion: Given that these differences appear to be mainly driven by the more pronounced obesity of the former patients, diet and exercise aiming at weight loss should constitute the cornerstone of management of PCOS and should be particularly emphasized in patients with the higher risk phenotypes of the syndrome.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome, Current Pharmaceutical Design 2016; 22 (36) . https://dx.doi.org/10.2174/1381612822666160720162707
DOI https://dx.doi.org/10.2174/1381612822666160720162707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Characterization of the Immune Inflammatory Profile in Obese Asthmatic Children
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic:The Two Faces of High-Density Lipoprotein (Executive Editor: Sophie Van Linthout)]
Current Pharmaceutical Design Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy Soy Protein Remnants Digested by Gastro-duodenal Proteases can Alter Microbial Interactions and Intestinal Cholesterol Absorption
Current Proteomics Crystal Structures of Phosphodiesterases and Implications on Substrate Specificity and Inhibitor Selectivity
Current Topics in Medicinal Chemistry Recent Advances in Cartilage Regenerative Technologies
Recent Patents on Biomedical Engineering (Discontinued) Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design A Prospective Study for Introducing Insulin Pens and Safety Needles in a Hospital Setting. The SANITHY Study
Current Diabetes Reviews Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy
Current Gene Therapy Antimalarials in the Treatment of Schistosomiasis
Current Pharmaceutical Design Comparison of Salivary Antioxidants and Oxidative Stress Status in Gestational Diabetes Mellitus and Healthy Pregnant Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Assessment of Structural Compatibility of Saxagliptin in Physical Mixtures with some excipient by Using HPLC
Current Pharmaceutical Analysis Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Alcohol Use Disorder and Dementia: Critical Mechanisms for Cognitive Loss
Current Neurovascular Research Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology